2023
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database
Gish R, Jacobson I, Lim J, Waters-Banker C, Kaushik A, Kim C, Cyhaniuk A, Wong R. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database. Hepatology 2023, 79: 1117-1128. PMID: 37976395, PMCID: PMC11020024, DOI: 10.1097/hep.0000000000000687.Peer-Reviewed Original ResearchConceptsHBV/HDV infectionLiver complicationsAll-Payer Claims DatabaseClaims databaseRisk of liver-related morbidityHepatitis delta virus infectionPrevalence of HDVDelta virus infectionProportion of patientsTime of diagnosisLiver-related morbidityUS insured populationHDV prevalenceHBV populationsHIV infectionCompensated cirrhosisDecompensated cirrhosisHBV infectionDelayed diagnosisHDV infectionHepatitis BViral hepatitisHBV/HDVPatient characteristicsSevere formScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosis
2018
An expert consensus for the management of chronic hepatitis B in Asian Americans
Tong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-viral therapyHepatocellular carcinomaHepatitis BHBV DNAPregnant womenBasal core promoter mutationsNegative chronic hepatitis BHepatitis B virus infectionAsian American physiciansLiver related deathManagement of HBVDetectable HBV DNAHBeAg-negative patientsHBsAg-positive patientsHBV DNA levelsNormal ALT levelsB virus infectionCore promoter mutationsHBsAg carrier rateLife-long surveillanceContrast CT scanAbdominal ultrasound examinationAlpha-fetoprotein testingAsian American patients
2017
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2015
Emerging trends in hepatocellular carcinoma incidence and mortality
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.Peer-Reviewed Original ResearchConceptsIB mortalityHCC incidenceHepatocellular carcinomaIncidence of HCCMultivariable Cox regression analysisOverall median survivalCox regression analysisEnd Results (SEER) dataSignificant survival improvementAge-adjusted incidenceU.S. populationHepatocellular carcinoma incidenceJoinpoint Regression ProgramIncidence-based mortalityRegression analysisSignificant increaseCurative modalityLiver transplantCurative stageMedian survivalSurvival improvementCarcinoma incidenceTumor sizeVascular invasionPrimary tumor